Key Points
- BridgeBio Pharma director Jennifer Cook sold 37,167 shares on June 24 at an average price of $70.00, totaling about $2.6 million. After the sale, she retained 8,383 shares, representing an 81.6% reduction in her position.
- The sale was made under a pre-arranged Rule 10b5-1 plan, meaning it was scheduled in advance rather than executed on a discretionary basis.
- BridgeBio’s stock was trading slightly higher and analysts remain bullish, with the shares up 0.9% to $69.26 and Wall Street assigning a “Moderate Buy” rating with an average price target of $92.90.
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Hannah Valantine sold 2,196 shares of the business's stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $68.57, for a total value of $150,579.72. Following the sale, the director directly owned 9,259 shares in the company, valued at $634,889.63. The trade was a 19.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Hannah Valantine also recently made the following trade(s):
- On Monday, June 22nd, Hannah Valantine sold 2,808 shares of BridgeBio Pharma stock. The shares were sold at an average price of $68.00, for a total value of $190,944.00.
BridgeBio Pharma Price Performance
NASDAQ:BBIO opened at $69.26 on Thursday. The firm has a market capitalization of $13.56 billion, a price-to-earnings ratio of -18.52 and a beta of 0.97. The business has a 50 day simple moving average of $69.20 and a 200-day simple moving average of $71.86. BridgeBio Pharma, Inc. has a 1 year low of $41.80 and a 1 year high of $84.94.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The firm had revenue of $194.51 million during the quarter, compared to analysts' expectations of $178.07 million. During the same quarter in the prior year, the company posted ($0.88) earnings per share. The business's revenue was up 66.8% on a year-over-year basis. As a group, analysts expect that BridgeBio Pharma, Inc. will post -2.29 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on BBIO shares. Truist Financial boosted their price objective on shares of BridgeBio Pharma from $95.00 to $102.00 and gave the company a "buy" rating in a research report on Wednesday, April 29th. Weiss Ratings restated a "sell (d)" rating on shares of BridgeBio Pharma in a report on Friday, May 15th. Citigroup started coverage on shares of BridgeBio Pharma in a research note on Tuesday, May 19th. They set a "neutral" rating and a $82.00 price target for the company. Canaccord Genuity Group started coverage on shares of BridgeBio Pharma in a report on Wednesday, June 3rd. They set a "buy" rating and a $104.00 price target on the stock. Finally, Barclays reiterated an "overweight" rating on shares of BridgeBio Pharma in a report on Tuesday, March 10th. Twenty-one equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, BridgeBio Pharma has an average rating of "Moderate Buy" and a consensus price target of $92.90.
Check Out Our Latest Stock Analysis on BridgeBio Pharma
Hedge Funds Weigh In On BridgeBio Pharma
Several hedge funds have recently bought and sold shares of the business. Global Retirement Partners LLC increased its stake in BridgeBio Pharma by 271.5% in the fourth quarter. Global Retirement Partners LLC now owns 509 shares of the company's stock worth $39,000 after purchasing an additional 372 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of BridgeBio Pharma by 91.4% during the fourth quarter. Farther Finance Advisors LLC now owns 513 shares of the company's stock valued at $39,000 after purchasing an additional 245 shares during the period. Kemnay Advisory Services Inc. purchased a new stake in shares of BridgeBio Pharma during the fourth quarter valued at $41,000. Cary Street Partners Investment Advisory LLC grew its holdings in shares of BridgeBio Pharma by 861.0% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 567 shares of the company's stock worth $43,000 after purchasing an additional 508 shares during the last quarter. Finally, Eurizon Capital SGR S.p.A. bought a new position in shares of BridgeBio Pharma in the fourth quarter worth about $44,000. Institutional investors own 99.85% of the company's stock.
BridgeBio Pharma Company Profile
(
Get Free Report)
BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.
BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
